Roth Capital Has Lowered Expectations for BioHarvest Sciences (NASDAQ:BHST) Stock Price

BioHarvest Sciences (NASDAQ:BHST) had its price target reduced by equities research analysts at Roth Capital from $10.00 to $8.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Roth Capital’s price target indicates a potential upside of 265.30% from the stock’s current price.

BHST has been the subject of a number of other research reports. Maxim Group set a $5.00 target price on shares of BioHarvest Sciences in a research note on Wednesday. Weiss Ratings raised BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioHarvest Sciences currently has an average rating of “Hold” and a consensus target price of $6.50.

BioHarvest Sciences Trading Up 5.3%

BHST traded up $0.11 during midday trading on Wednesday, hitting $2.19. 12,027 shares of the company were exchanged, compared to its average volume of 36,709. The firm’s 50 day moving average price is $2.74 and its 200-day moving average price is $3.80. BioHarvest Sciences has a 1-year low of $1.82 and a 1-year high of $12.80. The firm has a market capitalization of $42.97 million, a P/E ratio of -3.71 and a beta of 0.97. The company has a quick ratio of 2.44, a current ratio of 2.96 and a debt-to-equity ratio of 0.03.

BioHarvest Sciences (NASDAQ:BHST) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). The company had revenue of $8.84 million during the quarter, compared to analyst estimates of $9.45 million. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%. As a group, equities analysts forecast that BioHarvest Sciences will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On BioHarvest Sciences

Large investors have recently bought and sold shares of the stock. King Luther Capital Management Corp purchased a new position in BioHarvest Sciences during the fourth quarter worth about $208,000. Geode Capital Management LLC purchased a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $61,000. Thompson Siegel & Walmsley LLC bought a new position in shares of BioHarvest Sciences in the fourth quarter valued at approximately $1,945,000. HRT Financial LP purchased a new stake in shares of BioHarvest Sciences during the fourth quarter valued at approximately $75,000. Finally, Jane Street Group LLC bought a new stake in BioHarvest Sciences during the fourth quarter worth $145,000.

BioHarvest Sciences News Summary

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: BioHarvest secured an exclusive manufacturing and supply agreement for up to 20 tons of a rare botanical fragrance ingredient through 2027 and 2028. The company estimates the deal could generate approximately $20 million to $30 million in revenue and supports its strategy of building a higher-margin contract development and manufacturing (CDMO) business. BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
• Positive Sentiment: Second-quarter revenue increased 3.8% year over year to about $8.8 million. Management said spending is being directed toward manufacturing capacity, including the planned commercial fragrance production program, which it expects to support a path toward profitable CDMO growth. BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound
• Neutral Sentiment: Coverage of the earnings call and quarterly filing highlights the fragrance agreement, manufacturing expansion and broader botanical-synthesis strategy, but the new contract’s estimated revenue is largely scheduled for future years rather than the current quarter. BioHarvest Sciences Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Reported short interest was zero shares as of August 11, offering no evidence of meaningful short-selling pressure or a short-squeeze catalyst.
• Negative Sentiment: BioHarvest reported a second-quarter loss of $0.17 per share, worse than the expected $0.13 loss, while revenue of $8.84 million fell short of the $9.45 million consensus estimate. Net margin and return on equity remained negative. BioHarvest Sciences Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Fiscal 2026 revenue guidance of $37 million to $40 million is below the approximately $42.9 million analyst consensus, signaling that near-term growth may be slower than previously anticipated.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.